On Friday, 20 October 2017, Brazil delivered the following statement during TRIPS Council discussions on compulsory licensing. Brazil zeroed in a recent compulsory licensing case in Germany involving raltagravir, an antiretroviral.
As reported by Knowledge Ecology International (KEI), on 6 June 2017, the World Trade Organization (WTO), published a paper tabled by Brazil, China, Fiji, India, and South Africa entitled, “Intellectual Property and the Public Interest.” In their communication (IP/C/W/630), the proponents called for a series of discussions at the WTO TRIPS Council on Intellectual Property and the Public Interest. Continue Reading
On Friday, February 24, 2017, KEI hosted a meeting exploring compulsory licensing in the United States.
Title: History, Experiences, and Prospects of Compulsory Licensing on Medical Patents in the United States
Date: Friday February 24, 2017
Location: Kaiser Permanente Center for Total Health
700 Second St. NE (near Union Station)
Washington, DC 20002
On Wednesday, 9 November 2016, India delivered the following statement at the World Trade Organization’s (WTO) TRIPS Council’s discussions of the United Nations Secretary-General’s High Level Panel Report on Access to Medicines.
Agenda item 13: the United Nations Secretary-General’s High Level Panel Report on Access to Medicines
Statement by India.
Thank you Chairman.
At the outset, I would like to thank delegations of Brazil, China and South Africa who are also co-sponsors of this agenda item.
In a recent exchange with Senator Durbin, NIH Director Francis Collins expressed his concern that the NIH would alienate potential collaborators if the NIH applied the march-in remedy to address excessive prices of drugs. Continue Reading
(More on Colombia here: /colombia)
Continue Reading
On Thursday, May 21, 2015, KEI and KEI Europe hosted a side event at the 68th World Health Assembly on compulsory licensing of patents on drugs, vaccines, and diagnostic tests. The event was graciously hosted by UNAIDS in the Kofi Annan room.
Brian Arthur Pomper is a partner at the law firm of Akin Gump.
Mr. Pomper formerly served as chief international trade counsel to Senate Finance Committee Chairman Max Baucus (D-MT). In that role, he was responsible for advising Chairman Baucus and other members of the Senate Finance Committee on all aspects of the Committee’s international trade and economic agenda.
The following are four US Department of State cables discussing the status of Thailand as regards the USTR Special 301 review. KEI recently received the cables from the US Department of State in response to an earlier FOIA request.
The following discusses the 2009 PhRMA submission for the USTR Special 301 list on Thailand. Thailand is one of three Asian countries (China, Philippines and Thailand) that were singled out by PhRMA for the harshest treatment. The submission on Thailand covers several topics, including these: